Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.33 |
| ▸ | CDC42BPB | Q9Y5S2 | 12/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 11/20 | 0.33 |
| ▸ | CDC42BPA | Q5VT25 | 7/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.32 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.31 |
| ▸ | CHRNG | P07510 | 1/20 | 0.31 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRND | Q07001 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18969278 | 0.94 | CHRNA1 (0.35) | CHRNA1CHRNGCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL12257641 | 0.93 | CHRNA1 (0.34) | NAMPTCDC42BPBROCK1CDC42BPAROCK2 | |
| SCHEMBL18969263 | 0.92 | — | — | |
| SCHEMBL13406922 | 0.89 | SIGMAR1 (0.34) | SIGMAR1 | |
| SCHEMBL24606476 | 0.87 | SIGMAR1 (0.36) | SIGMAR1 | |
| SCHEMBL12257649 | 0.87 | CHRNA1 (0.38) | NAMPTCDC42BPBROCK1CHRNA1CHRNG | |
| SCHEMBL13337019 | 0.87 | SIGMAR1 (0.36) | SIGMAR1 | |
| SCHEMBL12403209 | 0.86 | NAMPT (0.32) | NAMPT | |
| SCHEMBL20926961 | 0.85 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL12403199 | 0.81 | CHEK1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023215801-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230203039-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | BRISTOL MYERS SQUIBB CO (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203039-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | BRISTOL MYERS SQUIBB CO (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-11524959-B1 | Indole and azaindole inhibitors of pad enzymes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-12-13 | — | — | US | disclosed |
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203039-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | PADI4, PADI1, PADI2 | NAMPT 1203/4885CDC42BPB 3438/4885ROCK1 2000/4885 |
| US-11524959-B1 | Indole and azaindole inhibitors of pad enzymes | PADI4, PADI1, PADI2 | NAMPT 1383/4885CDC42BPB 4021/4885ROCK1 1130/4885 |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADI4, PADI1, PADI2 | NAMPT 988/4885CDC42BPB 1871/4885ROCK1 3617/4885 |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI2, PADI6 | NAMPT 811/4885CDC42BPB 3442/4885ROCK1 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.